A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Patients With Immune (Idiopathic) Thrombocytopenia Purpura

NCT01071954 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

Thrombocytopenia in Pediatric Subjects With Immune Idiopathic Thrombocytopenic Purpura ITP

Interventions

BIOLOGICAL: Romiplostim

Sponsor

Amgen